USD10
KNSA Shares
About Kiniksa PharmaceuticalsKiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
USD10
KNSA Shares
About Kiniksa PharmaceuticalsKiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$6.22B
OPEN PRICE
$78.24
LOW (1Y)
$35.20
HIGH (1Y)
$82.94
LOW (24H)
$78.03
HIGH (24H)
$80.50
VOLUME (24H)
$430.28K
4.55%
Price history
Time | Price | Change |
|---|---|---|
Today | $78.24 | |
1 Day | $79.78 | 0.00% |
1 Week | $76.76 | |
1 Month | $77.60 | |
1 Year | $37.03 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.